This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dth.14068 What the physicians should know about mast cells, dendritic cells, urticaria and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Paulo Ricardo Criado, MD, PhD 1,2* , Carla Pagliari, BSc, PhD 3 , Roberta Fachini Jardim Criado, MD, PhD 1 , Gabriela Franco Marques, MD, PhD 2 , Walter Belda Junior, MD, PhD 2 1 Dermatology Department, Centro Universitário Saúde ABC, Santo André, São Paulo, Brazil. 2 Dermatology Department, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 3 Pathology Department, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Funds: none. Conflict of interest: none 04 figures 53 references Author Contributions: The authors made substantial contributions to the manuscript and are qualified as authors, participated sufficiently in the work to take public responsibility for appropriate portions of the content and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. PRC - conception and design, analysis and interpretation of data; This article is protected by copyright. All rights reserved.